Prevnar 13™ Home What is Prevnar 13™? Vaccination Schedule For Prevnar 13™ What Can Happen If My Child is Not Vaccinated? The Importance of an Additional Dose Important Safety Information Prescribing Information For US Health Care Professionals

Invasive pneumococcal disease (IPD) is still out there...

IPD includes meningitis, which remains a serious risk for children up to age 5. Untreated, meningitis can cause deafness and long-term brain damage. Even children who received the full 4-dose series of Prevnar^® might not be covered against 6 additional strains of bacteria that cause IPD.

...but so is more coverage for your child

That's where Prevnar 13^™ can help. Doctors at the CDC recommend that children under age 5 be vaccinated with Prevnar 13^™.

A single dose of Prevnar 13™ may be given to children 15 months to age 5 who have had 4 doses of Prevnar^® to get additional coverage.

The immune responses provided by this dose of Prevnar 13™ might not increase the number of antibodies ("infection-fighting cells") for the 6 additional strains (types 1, 3, 5, 6A, 7F, and 19A), as much as if your child had received the full 4 doses of Prevnar 13^™ (routinely given at 2, 4, 6, and 12 to 15 months). It's not known how medically important this difference is.

If your child has started receiving Prevnar^®, your child's doctor can switch to Prevnar 13^™ at any point for the remaining doses.

Ask your child's doctor today about additional coverage with Prevnar 13^™.

INDICATION FOR PREVNAR 13^™

Prevnar 13^™ is a vaccine approved for use in children 6 weeks through 5 years of age (prior to the 6^th birthday).

Prevnar 13^™ is indicated for active immunization for the prevention of invasive disease caused by 13 strains of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F).

Prevnar 13^™ is also indicated for the prevention of otitis media (ear infection) caused by 7 strains of Streptococcus pneumoniae (4, 6B, 9V, 14, 18C, 19F, and 23F). No efficacy data for ear infections are available for strains 1, 3, 5, 6A, 7F, and 19A.

IMPORTANT SAFETY INFORMATION FOR PREVNAR 13^™

• Prevnar 13^™ should not be given to anyone with a severe allergic reaction to any component of
  Prevnar 13^™, Prevnar^® or any diphtheria toxoid-containing vaccine.
• Prevnar 13^™ may not protect all individuals receiving the vaccine. Protection against ear infections is expected to be less than that for invasive disease. Children with weakened immune systems may have a reduced immune response to Prevnar 13^™. A temporary pause of breathing following vaccination has been observed in some infants born prematurely.
• The most commonly reported serious adverse events include bronchiolitis (an infection of the lungs) (0.9%, 1.1%), gastroenteritis (inflammation of the stomach and small intestine) (0.9%, 0.9%), and pneumonia (0.9%, 0.5%) for Prevnar 13^™ and Prevnar^®, respectively.
• The most common side effects are redness, swelling and tenderness at the injection site, fever, decreased appetite, irritability, increased sleep, and decreased sleep. Any side effects associated with the vaccination should be reported to your child's health care provider.
• Ask your child's health care provider about the risks, benefits and if Prevnar 13^™ is right for your child.

Please see Prescribing Information for PREVNAR 13^™ 

INDICATION FOR PREVNAR^®

Prevnar^® is indicated for active immunization of infants and toddlers against serious invasive disease caused by Streptococcus pneumoniae, including bacteremia (bloodstream infection) and meningitis (infection of the membranes surrounding the brain and spinal cord) caused by the seven serotypes in the vaccine. The seven serotypes (strains) of S. pneumoniae included in the vaccine (4, 6B, 9V, 14, 18C, 19F, and 23F) were the strains that most commonly caused these serious diseases in children prior to the introduction of the vaccine. The routine schedule is 2, 4, 6, and 12 to 15 months of age.

Prevnar^® is also indicated for immunization of infants and toddlers against otitis media (ear infections) caused by the seven serotypes in the vaccine. Protection against ear infections is expected to be less than that for invasive disease.

As with any vaccine, Prevnar^® may not protect all individuals receiving the vaccine from serious invasive disease caused by S. pneumoniae. This vaccine should not be used for treatment of active infection.

IMPORTANT SAFETY INFORMATION FOR PREVNAR^®

In clinical studies, the most frequently reported adverse events included injection site reactions, fever
(≥38°C/100.4°F), irritability, drowsiness, restless sleep, decreased appetite, vomiting, diarrhea, and rash.

Risks are associated with all vaccines, including Prevnar^®. Hypersensitivity to any vaccine component, including diphtheria toxoid, is a contraindication to its use. Prevnar^® does not protect 100% of children vaccinated. Immunization with Prevnar^® does not substitute for routine diphtheria immunization.

Please see Prescribing Information for PREVNAR^® 

The above Prescribing Information is available in PDF (portable document format).
PDF files require Adobe Reader; click here to download this free program.

Home  |  What is Prevnar 13^™?  |  Vaccination Schedule For Prevnar 13^™  |  What Can Happen If My Child is Not Vaccinated?
The Importance of an Additional Dose  |  Important Safety Information  |  Prescribing Information  |  For US Healthcare Professionals

	Manufactured by Wyeth Pharmaceuticals Inc.   Marketed by Pfizer Inc. 265708-01   © 2010 Pfizer Inc.   All rights reserved.   May 2010
This site is intended only for residents of the United States. All rights reserved. Please read our Privacy Policy, Terms and Conditions, and Global Privacy Principles.